Immunome (NASDAQ:IMNM) Trading Down 3.3%

Immunome, Inc. (NASDAQ:IMNM) shares traded down 3.3% during mid-day trading on Tuesday . The stock traded as low as $15.11 and last traded at $15.27. 616,752 shares traded hands during mid-day trading, a decline of 20% from the average session volume of 768,748 shares. The stock had previously closed at $15.79.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $33.00 price target on shares of Immunome in a research report on Tuesday, August 13th. Piper Sandler decreased their target price on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat, Immunome has an average rating of “Buy” and a consensus target price of $29.00.

Immunome Price Performance

The firm has a 50-day simple moving average of $14.34 and a 200 day simple moving average of $16.32. The company has a market capitalization of $923.52 million, a PE ratio of -2.04 and a beta of 1.77.

Immunome (NASDAQ:IMNM) last posted its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The company had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. Equities research analysts expect that Immunome, Inc. will post -1.92 EPS for the current fiscal year.

Insider Activity

In other Immunome news, Director Jean Jacques Bienaime purchased 7,000 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the purchase, the director now owns 16,615 shares in the company, valued at approximately $231,613.10. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Jean Jacques Bienaime purchased 7,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $13.94 per share, with a total value of $97,580.00. Following the completion of the transaction, the director now owns 16,615 shares of the company’s stock, valued at $231,613.10. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jack Higgins sold 3,524 shares of Immunome stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the sale, the insider now owns 16,000 shares of the company’s stock, valued at approximately $222,880. The disclosure for this sale can be found here. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several large investors have recently modified their holdings of IMNM. Quest Partners LLC bought a new stake in Immunome in the second quarter valued at about $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Immunome in the 2nd quarter valued at approximately $97,000. Arizona State Retirement System raised its position in shares of Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after acquiring an additional 918 shares in the last quarter. EntryPoint Capital LLC raised its position in shares of Immunome by 21,864.0% during the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after acquiring an additional 5,466 shares in the last quarter. Finally, Jump Financial LLC bought a new position in Immunome during the fourth quarter worth $172,000. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.